Spermosens AB (publ)
Spermosens AB (publ) provides diagnostic health care products and services in Sweden. The company offers devices for male infertility for fertility diagnostics and treatments for the IVF market. It develops JUNO-Checked, a device that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding. Spermosens AB (publ) was incorpora… Read more
Spermosens AB (publ) (9R5) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.075x
Based on the latest financial reports, Spermosens AB (publ) (9R5) has a cash flow conversion efficiency ratio of -0.075x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.60 Million) by net assets (€34.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Spermosens AB (publ) - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Spermosens AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Spermosens AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spermosens AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RJK Explorations Ltd
PINK:RJKAF
|
0.135x |
|
Burcon NutraScience Corp
PINK:BRCNF
|
0.640x |
|
Cymbria Corporation
PINK:CYMBF
|
0.002x |
|
Silver Sands Resources Corp
PINK:SSRSF
|
0.022x |
|
Longevity Health Holdings, Inc.
NASDAQ:XAGE
|
0.360x |
|
HAEMONETICS
MU:HAZ
|
0.056x |
|
Movinn AS
CO:MOVINN
|
0.254x |
|
Iiot-Oxys Inc
PINK:ITOX
|
0.015x |
Annual Cash Flow Conversion Efficiency for Spermosens AB (publ) (2021–2024)
The table below shows the annual cash flow conversion efficiency of Spermosens AB (publ) from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €27.34 Million | €-7.76 Million | -0.284x | +67.06% |
| 2023-12-31 | €12.69 Million | €-10.94 Million | -0.862x | +72.50% |
| 2022-12-31 | €5.83 Million | €-18.27 Million | -3.134x | -1229.38% |
| 2021-12-31 | €23.64 Million | €-5.57 Million | -0.236x | -- |